CHKP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Check Point Software Technologies Ltd is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has improving near-term momentum and a fresh analyst upgrade, but the broader Wall Street view is still mixed-to-cautious, hedge funds are selling, congress trading shows net selling, and the recent fundamentals were described as weak. Given the data, this is better treated as a hold rather than an immediate buy.
CHKP closed at 137.49, above the prior close and just above the first resistance area near 135.45, which shows short-term strength. MACD histogram is positive and expanding, supporting bullish momentum. However, RSI_6 at 78.79 is stretched, suggesting the move is already extended in the near term. Moving averages are converging, which points to a trend that is improving but not yet fully confirmed. Overall, the technical picture is constructive short term, but not an ideal fresh entry for an impatient buyer.
["Guggenheim upgraded CHKP to Buy with an $188 price target.", "Analysts said the stock may be undervalued and that bad news is already priced in.", "Check Point announced a $2 billion expansion of its share repurchase authorization.", "The AWS European Sovereign Cloud partnership supports product relevance and cloud-security expansion.", "The latest exposure-gap report highlights rising security threats, which can support demand for cybersecurity solutions."]
["Multiple firms recently cut price targets and several remain Neutral/Equal Weight.", "Recent quarterly results were described as weak, with disappointing demand and billing/product revenue trends.", "Guidance was reduced and analysts still question revenue reacceleration.", "Hedge funds are selling, with selling increasing 135.15% over the last quarter.", "Congress trading data shows 1 sale and 0 purchases in the last 90 days."]
Latest quarter data was not provided in usable detail, but the analyst commentary says the most recent quarter was disappointing, especially on demand-related metrics, billing, product revenue, and guidance. The latest quarter season referenced in the analyst notes is Q1 2026. The main takeaway is that growth momentum has been weak, and the market is waiting for clearer evidence of reacceleration.
Wall Street is split but still cautious overall. The recent trend includes one meaningful positive shift: Guggenheim upgraded CHKP to Buy and set an $188 target. However, the broader set of recent changes was negative, with BMO, BofA, Citi, Goldman Sachs, Morgan Stanley, and Scotiabank cutting targets or maintaining neutral/underweight-style views after a weak Q1 and reduced outlook. Pros: valuation support, recurring revenue quality, repurchase authorization, and potential upside if growth improves. Cons: weak demand, lowered guidance, and limited support from several major brokers. Overall analyst sentiment has improved at the margin but remains mixed.
